Dr Ajeet Singh

Adjunctive minocycline for major depressive disorder: A sub-study exploring peripheral immune-inflammatory markers and associated treatment response

A Walker, M Mohebbi, M Maes, M Berk, K Walder, C Bortolasci, Z Liu, C Ng, M Ashton, L Berk, A Singh, G Malhi, O Dean

(2023), Vol. 27, Brain, Behavior, and Immunity - Health, C1

Guidelines for the management of psychosis in the context of mood disorders

D Bassett, P Boyce, B Lyndon, R Mulder, G Parker, R Porter, A Singh, E Bell, A Hamilton, G Morris, G Malhi

(2022), Vol. 241, pp. 187-196, Schizophrenia Research, Amsterdam, The Netherlands, C1

An Evidence-Based Perspective on The 2020 Royal Australian and New Zealand College of Psychiatrists Clinical Practice Guidelines

G Malhi, E Bell, D Bassett, P Boyce, R Bryant, P Hazell, M Hopwood, B Lyndon, R Mulder, R Porter, A Singh, G Murray

(2022), Vol. 30, pp. 447-451, Australasian Psychiatry, C1

Minocycline as adjunctive treatment for major depressive disorder: Pooled data from two randomized controlled trials

R Zazula, M Husain, M Mohebbi, A Walker, I Chaudhry, A Khoso, M Ashton, B Agustini, N Husain, J Deakin, A Young, M Berk, B Kanchanatawan, C Ng, M Maes, L Berk, A Singh, G Malhi, O Dean

(2021), Vol. 55, pp. 784-798, Australian and New Zealand Journal of Psychiatry, England, C1

The 2020 Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders

G Malhi, E Bell, D Bassett, P Boyce, R Bryant, P Hazell, M Hopwood, B Lyndon, R Mulder, R Porter, A Singh, G Murray

(2021), Vol. 55, pp. 7-117, Australian and New Zealand Journal of Psychiatry, London, Eng., C1

Profiling rTMS: a critical response

G Malhi, E Bell, Z Mannie, D Bassett, P Boyce, M Hopwood, R Mulder, R Porter, A Singh, B Lyndon

(2021), Vol. 55, pp. 355-365, Australian and New Zealand journal of psychiatry, London, Eng., C1

Is rTMS Ready for Primetime?

G Malhi, E Bell, T Outhred, A Singh, M Hopwood, R Mulder, D Bassett, Z Mannie

(2021), Vol. 66, pp. 873-877, Canadian Journal of Psychiatry, United States, C1

Personality disorder and functioning in major depressive disorder: a nested study within a randomized controlled trial

Bianca Kavanagh, Lana Williams, Michael Berk, Alyna Turner, Henry Jackson, Mohammadreza Mohebbi, Buranee Kanchanatawan, Melanie Ashton, Chee Ng, Michael Maes, Lesley Berk, Gin Malhi, Nathan Dowling, Ajeet Singh, Olivia Dean

(2020), Vol. 42, pp. 14-21, Brazilian journal of psychiatry, Sao Paulo, Brazil, C1

A pragmatic randomized controlled trial exploring the relationship between pulse number and response to repetitive transcranial magnetic stimulation treatment in depression

P Fitzgerald, K Hoy, J Reynolds, A Singh, R Gunewardene, C Slack, S Ibrahim, Z Daskalakis

(2020), Vol. 13, pp. 145-152, Brain stimulation, Amsterdam, The Netherlands, C1

Switching antidepressants in the treatment of major depression: when, how and what to switch to?

P Boyce, M Hopwood, G Morris, A Hamilton, D Bassett, B Baune, R Mulder, R Porter, G Parker, A Singh, T Outhred, P Das, G Malhi

(2020), Vol. 261, pp. 160-163, Journal of affective disorders, Amsterdam, The Netherlands, C1

Acute coronary syndrome-associated depression: getting to the heart of the data

G Parker, D Bassett, P Boyce, B Lyndon, R Mulder, R Porter, A Singh, E Bell, A Hamilton, G Morris, M Spoelma, G Malhi

(2020), Vol. 269, pp. 70-77, Journal of affective disorders, Amsterdam, The Netherlands, C1

The protective effects of human milk-derived peptides on the pancreatic islet biology

A Singh, A Kumar Enjapoori, Y Gibert, K Dwyer

(2020), Vol. 9, Biology Open, England, C1

The 2020 Royal Australian and New Zealand College of psychiatrists clinical practice guidelines for mood disorders: Bipolar disorder summary

G Malhi, E Bell, P Boyce, D Bassett, M Berk, R Bryant, M Gitlin, A Hamilton, P Hazell, M Hopwood, B Lyndon, R McIntyre, G Morris, R Mulder, R Porter, A Singh, L Yatham, A Young, G Murray

(2020), Vol. 22, pp. 805-821, Bipolar Disorders, London, Eng., C1

The 2020 Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders: Major depression summary

G Malhi, E Bell, A Singh, D Bassett, M Berk, P Boyce, R Bryant, M Gitlin, A Hamilton, P Hazell, M Hopwood, B Lyndon, R McIntyre, G Morris, R Mulder, R Porter, L Yatham, A Young, G Murray

(2020), Vol. 22, pp. 788-804, Bipolar Disorders, London, Eng., C1

Cognitive side-effects of electroconvulsive therapy: what are they, how to monitor them and what to tell patients

Richard Porter, Bernhard Baune, Grace Morris, Amber Hamilton, Darryl Bassett, Philip Boyce, Malcolm Hopwood, Roger Mulder, Gordon Parker, Ajeet Singh, Tim Outhred, Pritha Das, Gin Malhi

(2020), Vol. 6, pp. 1-7, BJPsych open, Cambridge, Eng., C1

The role of depression pharmacogenetic decision support tools in shared decision making

K Arandjelovic, H Eyre, E Lenze, A Singh, M Berk, C Bousman

(2019), Vol. 126, pp. 87-94, Journal of Neural Transmission, Austria, C1

Moving pharmacoepigenetics tools for depression toward clinical use

Laura Hack, Gabriel Fries, Harris Eyre, Chad Bousman, Ajeet Singh, Joao Quevedo, Vineeth John, Bernhard Baune, Boadie Dunlop

(2019), Vol. 249, pp. 336-346, Journal of affective disorders, Amsterdam, The Netherlands, C1

Stepwise treatment of acute bipolar depression

G Parker, G Malhi, A Hamilton, G Morris, G Tavella, D Bassett, B Baune, P Boyce, M Hopwood, R Mulder, R Porter, T Outhred, P Das, A Singh

(2019), Vol. 21, pp. 465-469, Bipolar disorders, Chichester, Eng., C1

The limitations of using randomised controlled trials as a basis for developing treatment guidelines

R Mulder, A Singh, A Hamilton, P Das, T Outhred, G Morris, D Bassett, B Baune, M Berk, P Boyce, B Lyndon, G Parker, G Malhi

(2018), Vol. 21, pp. 4-6, Evidence-Based Mental Health, England, C1

Cognition in depression: can we THINC-it better?

B Baune, G Malhi, G Morris, T Outhred, A Hamilton, P Das, D Bassett, M Berk, P Boyce, B Lyndon, R Mulder, G Parker, A Singh

(2018), Vol. 225, pp. 559-562, Journal of affective disorders, Amsterdam, The Netherlands, C1

Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders: bipolar disorder summary.

Gin Malhi, Tim Outhred, Grace Morris, Philip Boyce, Richard Bryant, Paul Fitzgerald, Malcolm Hopwood, Bill Lyndon, Roger Mulder, Greg Murray, Richard Porter, Ajeet Singh, Kristina Fritz

(2018), Vol. 208, pp. 219-225, Medical journal of Australia, London, Eng., C1

Pharmacogenetic guidelines and decision support tools for depression treatment: application to late-life

Donald Chang, Harris Eyreeuro, Ryan Abbott, Michael Coudreaut, Bernhard Baune, Jeffrey Shaman, Helen Lavretsky, Eric Lenze, David Merrill, Ajeet Singh, Benoit Mulsant, Charles Reynolds, Daniel Müller, Chad Bousman

(2018), Vol. 19, pp. 1269-1284, Pharmacogenomics, London, Eng., C1

Beyond the therapeutic shackles of the monoamines: new mechanisms in bipolar disorder biology

J Data-Franco, A Singh, D Popovic, M Ashton, M Berk, E Vieta, M Figueira, O Dean

(2017), Vol. 72, pp. 73-86, Progress in neuro-psychopharmacology & biological psychiatry, Amsterdam, The Netherlands, C1

Concordance between actual and pharmacogenetic predicted desvenlafaxine dose needed to achieve remission in major depressive disorder: A 10-week open-label study

C Bousman, D Müller, C Ng, K Byron, M Berk, A Singh

(2017), Vol. 27, pp. 1-6, Pharmacogenetics and Genomics, United States, C1

Adjunctive minocycline treatment for major depressive disorder: A proof of concept trial

O Dean, B Kanchanatawan, M Ashton, M Mohebbi, C Ng, M Maes, L Berk, A Sughondhabirom, S Tangwongchai, A Singh, H McKenzie, D Smith, G Malhi, N Dowling, M Berk

(2017), Vol. 51, pp. 829-840, Australian and New Zealand Journal of Psychiatry, England, C1

Defining melancholia: A core mood disorder

G Parker, D Bassett, T Outhred, G Morris, A Hamilton, P Das, B Baune, M Berk, P Boyce, B Lyndon, R Mulder, A Singh, G Malhi

(2017), Vol. 19, pp. 235-237, Bipolar Disorders, Denmark, C1

Psychotropic pharmacogenetics - distraction or destiny?

A Singh, B Baune, A Hamilton, P Das, T Outhred, G Morris, D Bassett, M Berk, P Boyce, B Lyndon, R Mulder, G Parker, G Malhi

(2017), Vol. 51, pp. 665-667, Australian & New Zealand journal of psychiatry, London, Eng., C1

Mixed mood: the not so united states?

G Malhi, M Berk, G Morris, A Hamilton, T Outhred, P Das, D Bassett, B Baune, P Boyce, B Lyndon, R Mulder, G Parker, A Singh

(2017), Vol. 19, pp. 242-245, Bipolar Disorders, Hoboken, N. J., C1

Staging in bipolar disorder: from theoretical framework to clinical utility

M Berk, R Post, A Ratheesh, E Gliddon, A Singh, E Vieta, A Carvalho, M Ashton, L Berk, S Cotton, P McGorry, B Fernandes, L Yatham, S Dodd

(2017), Vol. 16, pp. 236-244, World psychiatry, Chichester, Eng., C1

Stimulants for depression: On the up and up?

G Malhi, Y Byrow, D Bassett, P Boyce, M Hopwood, W Lyndon, R Mulder, R Porter, A Singh, G Murray

(2016), Vol. 50, pp. 203-207, Australian & New Zealand journal of psychiatry, London, Eng., C1

Why the hype about subtype? Bipolar I, bipolar II - it's simply bipolar, through and through!

G Malhi, Y Byrow, P Boyce, D Bassett, P Fitzgerald, M Hopwood, W Lyndon, R Mulder, G Murray, A Singh, R Bryant, R Porter

(2016), Vol. 50, pp. 303-306, Australian & New Zealand journal of psychiatry, London, Eng., C1

Mental health system development in Asia: Does Australia have a role?

K Arandjelovic, H Eyre, M Forbes, R Bauer, S Aggarwal, A Singh, B Baune, I Everall, M Berk, C Ng

(2016), Vol. 50, pp. 834-841, Australian and New Zealand Journal of Psychiatry, England, C1

A brief review of exercise, bipolar disorder, and mechanistic pathways.

D Thomson, A Turner, S Lauder, M Gigler, L Berk, A Singh, J Pasco, M Berk, L Sylvia

(2015), Vol. 6, pp. 147-147, Frontiers in Psychology, Switzerland, C1

Homocysteine as a potential biomarker in bipolar disorders: a critical review and suggestions for improved studies

A Ghanizadeh, A Singh, M Berk, M Torabi-Nami

(2015), Vol. 19, pp. 1-13, Expert opinion on therapeutic targets, Oxford, Eng., C1

Effects of persisting emotional impact from child abuse and norepinephrine transporter genetic variation on antidepressant efficacy in major depression: a pilot study

A Singh, C Bousman, C Ng, K Byron, M Berk

(2015), Vol. 13, pp. 53-61, Clinical psychopharmacology and neuroscience, Korea (South), C1

Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders

G Malhi, D Bassett, P Boyce, R Bryant, P Fitzgerald, K Fritz, M Hopwood, B Lyndon, R Mulder, G Murray, R Porter, A Singh

(2015), Vol. 49, pp. 1087-1206, Australian and New Zealand journal of psychiatry, Carlton South, Vic., C1

Improved Antidepressant Remission in Major Depression via a Pharmacokinetic Pathway Polygene Pharmacogenetic Report

A Singh

(2015), Vol. 13, pp. 150-156, Clinical Psychopharmacology and Neuroscience, Korea (South), C1-1

Escitalopram efficacy in depression a cross-ethnicity examination of the serotonin transporter promoter polymorphism

C Bousman, J Sarris, E Won, H Chang, A Singh, H Lee, B Ham, C Tan, M Lee, C Ng

(2014), Vol. 34, pp. 1-4, Journal of clinical psychopharmacology, London, England, C1

Atypical antipsychotic agents; peas in a pod or chalk and cheese?

A Singh, A Nierenberg, L Yatham, M Berk

(2014), Vol. 12, pp. 1-4, BMC Medicine, London, England, C1

Psychomotor depressive symptoms may differentially respond to venlafaxine

A Singh, C Bousman, C Ng, K Byron, M Berk

(2013), Vol. 28, pp. 121-126, International clinical psychopharmacology, Philadelphia, Pa., C1

Antidepressant pharmacogenetics

A Singh, C Bousman, C Ng, M Berk

(2013), Vol. 27, pp. 43-51, Current Opinion in Psychiatry, Philadelphia, PA, C1

High impact child abuse may predict risk of elevated suicidality during antidepressant initiation

A Singh, C Bousman, C Ng, M Berk

(2013), Vol. 47, pp. 1191-1195, Australian & New Zealand journal of psychiatry, London, Eng., C1-1

Pharmacogenetic polymorphisms and response to escitalopram and venlafaxine over 8 weeks in major depression

C Ng, J Sarris, A Singh, C Bousman, K Byron, L Peh, D Smith, C Tan, I Schweitzer

(2013), Vol. 28, pp. 516-522, Human psychopharmacology: clinical and experimental, Chichester, Eng., C1-1

Equivalent beneficial effects of unilateral and bilateral prefrontal cortex transcranial magnetic stimulation in a large randomized trial in treatment-resistant major depression

P Fitzgerald, K Hoy, A Singh, R Gunewardene, C Slack, S Ibrahim, P Hall, Z Daskalakis

(2013), Vol. 16, pp. 1975-1984, International journal of neuropsychopharmacology, Oxford, Eng., C1-1

Treatment of bipolar depression

Michael Berk, Lesley Berk, Christopher Davey, Steven Moylan, Francesco Giorlando, Ajeet Singh, Harish Kalra, Seetal Dodd, Gin Malhi

(2013), Vol. 199, pp. S32-S35, Medical Journal of Australia, London, Eng., C1-1

ABCB1 polymorphism predicts escitalopram dose needed for remission in major depression

A Singh, C Bousman, C Ng, K Byron, M Berk

(2012), Vol. 2, pp. 1-6, Translational psychiatry, London, England, C1

A consensus statement for safety monitoring guidelines of treatments for major depressive disorder

S Dodd, G Malhi, J Tiller, I Schweitzer, I Hickie, J Khoo, D Bassett, B Lyndon, P Mitchell, G Parker, P Fitzgerald, M Udina, A Singh, S Moylan, F Giorlando, C Doughty, C Davey, M Theodoros, M Berk

(2011), Vol. 45, pp. 712-725, Australian and New Zealand journal of psychiatry, London, England, C1

Summary of Guideline for the Treatment of Bipolar Disorder

Philip Mitchell, Gin Malhi, Bernette Redwood, Jillian Ball

(2003), Vol. 11, pp. 39-53, Australasian Psychiatry, C1-1